ALC ALCON INC IFRS
Ophthalmic Goods · NYSE · SEC CIK 1167379 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY4.9%
TTM net income YoY-3.7%
TTM EPS YoY-3.4%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR43.0%
Margins
Gross margin55.2%
Operating margin13.1%
Net margin9.4%
FCF margin16.6%
EBITDA margin—
Returns
ROE4.5%
ROA3.2%
ROIC (approx.)4.6%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets30.2%
Debt / equity0.21x
Current ratio2.12x
Interest coverage6.67x
Cash quality & payout
Operating cash flow / net income2.32x
Accruals ratio-4.2%
Payout ratio16.9%
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $10.40B | $9.91B | $9.46B | $8.72B | $8.29B |
| Cost of revenue | $4.59B | $4.33B | $4.14B | $3.91B | $3.58B |
| Gross profit | $5.75B | $5.51B | $5.25B | $4.75B | $4.65B |
| R&D expense | $990.00M | $876.00M | $828.00M | $702.00M | $842.00M |
| SG&A expense | $3.45B | $3.25B | $3.21B | $3.07B | $3.08B |
| Operating income | $1.36B | $1.41B | $1.04B | $672.00M | $580.00M |
| Interest expense | $204.00M | $192.00M | $189.00M | $134.00M | $120.00M |
| Pretax income | $1.16B | $1.26B | $832.00M | $463.00M | $418.00M |
| Income tax | $180.00M | $238.00M | -$142.00M | $128.00M | $42.00M |
| Net income | $980.00M | $1.02B | $974.00M | $335.00M | $376.00M |
| EPS (basic) | 1.99 | 2.06 | 1.98 | 0.68 | 0.77 |
| EPS (diluted) | 1.98 | 2.05 | 1.96 | 0.68 | 0.76 |
| Weighted avg. shares (diluted) | 496.20M | 497.50M | 496.50M | 494.40M | 493.40M |
| Balance sheet | |||||
| Cash & equivalents | $1.53B | $1.68B | $1.09B | $980.00M | $1.57B |
| Short-term investments | $80.00M | $153.00M | $0 | $0 | $3.00M |
| Receivables | $1.94B | $1.74B | $1.77B | $1.67B | $1.50B |
| Inventory | $2.39B | $2.27B | $2.32B | $2.11B | $1.90B |
| Current assets | $6.45B | $6.31B | $5.65B | $5.19B | $5.39B |
| PP&E, netmay include right-of-use assets (IFRS) | $4.77B | $4.39B | $4.37B | $4.03B | $3.71B |
| Goodwill | $9.26B | $8.95B | $8.93B | $8.93B | $8.90B |
| Intangibles | $9.01B | $8.59B | $9.06B | $9.69B | $8.77B |
| Total assets | $31.55B | $30.35B | $29.61B | $29.16B | $28.00B |
| Current liabilities | $3.05B | $2.28B | $2.40B | $2.74B | $2.47B |
| Short-term debt | $575.00M | $105.00M | $63.00M | $107.00M | $114.00M |
| Long-term debt | $4.16B | $4.54B | $4.68B | $4.54B | $3.97B |
| Total debt | $4.74B | $4.64B | $4.74B | $4.65B | $4.08B |
| Total liabilities | $9.52B | $8.79B | $8.99B | $9.49B | $8.74B |
| Shareholders' equity | $22.03B | $21.55B | $20.62B | $19.68B | $19.26B |
| Net debt | $3.21B | $2.97B | $3.65B | $3.67B | $2.50B |
| Cash flow statement | |||||
| Operating cash flow | $2.27B | $2.08B | $1.39B | $1.22B | $1.34B |
| Capital expenditure | $543.00M | $473.00M | $658.00M | $636.00M | $700.00M |
| Free cash flow | $1.73B | $1.60B | $730.00M | $581.00M | $645.00M |
| Investing cash flow | -$1.34B | -$1.17B | -$1.09B | -$1.86B | -$1.20B |
| Financing cash flow | -$1.12B | -$322.00M | -$211.00M | -$8.00M | -$123.00M |
| Stock-based compensation | $171.00M | $162.00M | $159.00M | $152.00M | $151.00M |
| Dividends paid | $166.00M | $130.00M | $116.00M | $100.00M | $54.00M |
| Share buybacks | $676.00M | $0 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.